Drug intelligence / Profile preview

BDB001

Development stage: Phase 3
Lead developer: Eikon Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

BDB001, also known as EIK1001, is a clinical-stage immune modulator that acts as an agonist for Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). Originally developed by Seven and Eight Biopharmaceuticals, it was later acquired by Eikon Therapeutics. It is being investigated for the treatment of advanced solid tumors, both as a single agent and in combination with other immunotherapies like pembrolizumab and atezolizumab.

Other names: EIK1001EIK-1001EIK 1001BDB001BDB-001BDB 001

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on BDB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDB001.

Explore the full profile